Golden, CO – According to filings with the U.S. Securities and Exchange Commission, BioIntelliSense is raising $44,985,854.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, James Mault played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About BioIntelliSense
BioIntelliSense has enabled medical-grade Remote Patient Monitoring Hospital at Home (RPM-H@H) via its BioSticker-based data service. The BioSticker is an FDA-cleared 510k class II wearable medical device that enables at-home continuous monitoring of vital signs and symptoms directly associated with COVID-19 (temperature, respiratory rate at rest, and coughing frequency) for 30 days on a single device without recharging.

To learn more about BioIntelliSense, visit http://biointellisense.com/

Contact:
James Mault, Chief Executive Officer
303-578-2648

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved